Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
Identifieur interne : 000096 ( Ncbi/Checkpoint ); précédent : 000095; suivant : 000097Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
Auteurs : Ron Tintner [États-Unis] ; Prasad Manian ; Polly Gauthier ; Joseph Jankovic [États-Unis]Source :
- Archives of neurology [ 0003-9942 ] ; 2005.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (chemistry), Benzothiazoles, Dopamine Agonists (adverse effects), Dopamine Agonists (chemistry), Drug Administration Schedule, Humans, Lung (drug effects), Lung (pathology), Lung (radiography), Male, Molecular Structure, Parkinson Disease (drug therapy), Pergolide (adverse effects), Pergolide (chemistry), Pleura (drug effects), Pleura (pathology), Pleura (radiography), Pleural Diseases (chemically induced), Pleural Diseases (pathology), Pleural Diseases (radiography), Pulmonary Fibrosis (chemically induced), Pulmonary Fibrosis (pathology), Pulmonary Fibrosis (radiography), Thiazoles (therapeutic use), Tomography, X-Ray Computed.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Pergolide.
- chemical , chemistry : Antiparkinson Agents, Dopamine Agonists, Pergolide.
- chemically induced : Pleural Diseases, Pulmonary Fibrosis.
- drug effects : Lung, Pleura.
- drug therapy : Parkinson Disease.
- pathology : Lung, Pleura, Pleural Diseases, Pulmonary Fibrosis.
- radiography : Lung, Pleura, Pleural Diseases, Pulmonary Fibrosis.
- chemical , therapeutic use : Thiazoles.
- Aged, Benzothiazoles, Drug Administration Schedule, Humans, Male, Molecular Structure, Tomography, X-Ray Computed.
Abstract
Dopamine agonists are increasingly used in the treatment of Parkinson disease, but they may cause serious adverse effects. In December 1983, symptoms of Parkinson disease developed in a 55-year-old man with no history of pulmonary disease, smoking, or asbestos exposure. He began treatment with dopamine agonists bromocriptine mesylate (in 1984) and pergolide mesylate (in 1989). In late 2000, pulmonary symptoms developed. Chest radiographs and computed tomographic findings showed a mass in the right upper lobe and effusion. A biopsy specimen showed pleural and parenchymal fibrosis. This syndrome resolved after cessation of pergolide therapy and a switch to pramipexole dihydrochloride. This case draws attention to the association of long-term ergot dopamine agonist therapy with pleuropulmonary fibrosis, which can develop as late as 11 years after the initiation of therapy. We also review evidence that the risk of this complication is substantially lower with the newer nonergot dopamine agonists.
DOI: 10.1001/archneur.62.8.1290
PubMed: 16087771
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000194
- to stream PubMed, to step Curation: 000194
- to stream PubMed, to step Checkpoint: 000191
- to stream Ncbi, to step Merge: 000096
- to stream Ncbi, to step Curation: 000096
Links to Exploration step
pubmed:16087771Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.</title><author><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, USA. rtintner@tmh.tmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston</wicri:regionArea><wicri:noRegion>Houston</wicri:noRegion></affiliation></author><author><name sortKey="Manian, Prasad" sort="Manian, Prasad" uniqKey="Manian P" first="Prasad" last="Manian">Prasad Manian</name></author><author><name sortKey="Gauthier, Polly" sort="Gauthier, Polly" uniqKey="Gauthier P" first="Polly" last="Gauthier">Polly Gauthier</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1001/archneur.62.8.1290</idno><idno type="RBID">pubmed:16087771</idno><idno type="pmid">16087771</idno><idno type="wicri:Area/PubMed/Corpus">000194</idno><idno type="wicri:Area/PubMed/Curation">000194</idno><idno type="wicri:Area/PubMed/Checkpoint">000191</idno><idno type="wicri:Area/Ncbi/Merge">000096</idno><idno type="wicri:Area/Ncbi/Curation">000096</idno><idno type="wicri:Area/Ncbi/Checkpoint">000096</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.</title><author><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, USA. rtintner@tmh.tmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston</wicri:regionArea><wicri:noRegion>Houston</wicri:noRegion></affiliation></author><author><name sortKey="Manian, Prasad" sort="Manian, Prasad" uniqKey="Manian P" first="Prasad" last="Manian">Prasad Manian</name></author><author><name sortKey="Gauthier, Polly" sort="Gauthier, Polly" uniqKey="Gauthier P" first="Polly" last="Gauthier">Polly Gauthier</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j">Archives of neurology</title><idno type="ISSN">0003-9942</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (chemistry)</term><term>Benzothiazoles</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (chemistry)</term><term>Drug Administration Schedule</term><term>Humans</term><term>Lung (drug effects)</term><term>Lung (pathology)</term><term>Lung (radiography)</term><term>Male</term><term>Molecular Structure</term><term>Parkinson Disease (drug therapy)</term><term>Pergolide (adverse effects)</term><term>Pergolide (chemistry)</term><term>Pleura (drug effects)</term><term>Pleura (pathology)</term><term>Pleura (radiography)</term><term>Pleural Diseases (chemically induced)</term><term>Pleural Diseases (pathology)</term><term>Pleural Diseases (radiography)</term><term>Pulmonary Fibrosis (chemically induced)</term><term>Pulmonary Fibrosis (pathology)</term><term>Pulmonary Fibrosis (radiography)</term><term>Thiazoles (therapeutic use)</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Pergolide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Pergolide</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Pleural Diseases</term><term>Pulmonary Fibrosis</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lung</term><term>Pleura</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term><term>Pleura</term><term>Pleural Diseases</term><term>Pulmonary Fibrosis</term></keywords><keywords scheme="MESH" qualifier="radiography" xml:lang="en"><term>Lung</term><term>Pleura</term><term>Pleural Diseases</term><term>Pulmonary Fibrosis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Thiazoles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Benzothiazoles</term><term>Drug Administration Schedule</term><term>Humans</term><term>Male</term><term>Molecular Structure</term><term>Tomography, X-Ray Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine agonists are increasingly used in the treatment of Parkinson disease, but they may cause serious adverse effects. In December 1983, symptoms of Parkinson disease developed in a 55-year-old man with no history of pulmonary disease, smoking, or asbestos exposure. He began treatment with dopamine agonists bromocriptine mesylate (in 1984) and pergolide mesylate (in 1989). In late 2000, pulmonary symptoms developed. Chest radiographs and computed tomographic findings showed a mass in the right upper lobe and effusion. A biopsy specimen showed pleural and parenchymal fibrosis. This syndrome resolved after cessation of pergolide therapy and a switch to pramipexole dihydrochloride. This case draws attention to the association of long-term ergot dopamine agonist therapy with pleuropulmonary fibrosis, which can develop as late as 11 years after the initiation of therapy. We also review evidence that the risk of this complication is substantially lower with the newer nonergot dopamine agonists.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><noCountry><name sortKey="Gauthier, Polly" sort="Gauthier, Polly" uniqKey="Gauthier P" first="Polly" last="Gauthier">Polly Gauthier</name><name sortKey="Manian, Prasad" sort="Manian, Prasad" uniqKey="Manian P" first="Prasad" last="Manian">Prasad Manian</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name></noRegion><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000096 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000096 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:16087771
|texte= Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:16087771" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |